Find information on thousands of medical conditions and prescription drugs.

Fulvestrant

Fulvestrant is a drug treatment of hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects and down-regulates the estrogen receptor. It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Once-monthly treatment for refractory breast cancer
From Nursing, 8/1/02

The FDA has approved Faslodex (fulvestrant) injection for the treatment of hormone receptor-- positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy, such as tamoxifen. The only estrogen receptor antagonist to be proven effective after tamoxifen failure, Faslodex doesn't cause the adverse reactions commonly associated with cytotoxic chemotherapy. It's administered once monthly as an I.M. injection.

The FDA's approval of Faslodex was based on data from two Phase III randomized multicenter studies involving 851 patients. Its effectiveness when given as a 250-mg once-monthly injection was established by comparison with the selective aromatase inhibitor anastrozole (1 mg/day orally).

A product of AstaZeneca, Faslodex can cause fetal harm when administered to a pregnant woman. Warn women of childbearing potential not to become pregnant.

Copyright Springhouse Corporation Aug 2002
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Fulvestrant
Home Contact Resources Exchange Links ebay